What is OWKIN?
OWKIN, headquartered in New York, is at the forefront of applying artificial intelligence technologies to revolutionize clinical research. The company specializes in developing interpretable machine learning models that leverage data from healthcare and research activities. This innovative approach empowers researchers to derive deeper insights and accelerate drug discovery and development processes, positioning OWKIN as a key enabler in the healthtech and AI-driven biomedical sectors.
How much funding has OWKIN raised?
OWKIN has raised a total of $225.1M across 4 funding rounds:
Angel/Seed
$2.1M
Other Financing Round
$25M
Series A
$18M
Private Equity
$180M
Angel/Seed (2016): $2.1M, investors not publicly disclosed
Other Financing Round (2020): $25M led by Bpifrance Large Venture
Series A (2020): $18M supported by Bpifrance and Mubadala GE Capital PJSC
Private Equity (2021): $180M featuring Sanofi
Key Investors in OWKIN
Bpifrance
Bpifrance is a French public investment bank that finances companies across all stages of development, providing credit, guarantees, and equity. They support innovation, international expansion, and offer acceleration programs for startups and SMEs.
Mubadala GE Capital PJSC
Mubadala GE Capital PJSC is an investment entity that has participated in OWKIN's funding rounds. Further details on their specific investment focus are not publicly disclosed.
Sanofi
Sanofi is a global biopharmaceutical company focused on discovering, developing, and delivering medicines and vaccines. Their investment in OWKIN highlights a strategic interest in leveraging AI for advancements in drug development and clinical research.
What's next for OWKIN?
With a substantial financial backing, OWKIN is poised for an accelerated growth trajectory. The enterprise-level funding indicates a transition into a scaling phase, likely focusing on expanding its technological capabilities, broadening its research partnerships, and increasing its global footprint. Future strategic initiatives may involve further integration of AI into complex clinical trial designs and enhancing data security and privacy protocols to foster greater trust and collaboration within the healthcare ecosystem.
See full OWKIN company page
